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Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric brain cancer with no
effective therapy. Histological similarity of DIPG to supratentorial high-grade astrocytomas
of adults has led to assumptions that these entities possess similar underlying molecular
properties and therefore similar therapeutic responses to standard therapies. The failure
of all clinical trials in the last 30 years to improve DIPG patient outcome has sug-
gested otherwise. Recent studies employing next-generation sequencing and microarray
technologies have provided a breadth of evidence highlighting the unique molecular
genetics and epigenetics of this cancer, distinguishing it from both adult and pediatric
cerebral high-grade astrocytomas. This review describes the most common molecular
genetic and epigenetic signatures of DIPG in the context of molecular subgroups and
histopathological diagnosis, including this tumor entity’s unique mutational landscape,
copy number alterations, and structural variants, as well as epigenetic changes on
the global DNA and histone levels. The increased knowledge of DIPG biology and
histopathology has opened doors to new diagnostic and therapeutic avenues.
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Introduction
Diffuse intrinsic pontine gliomas (DIPG), brainstem tumors that diffusely involve the pons, are the
most common type of brainstem gliomas (BSG) (1). The mean age of diagnosis for this devastating
pediatric neoplasm is 6–7 years (2, 3). The delicate location of these tumors eliminates surgical
intervention as a treatment option. Radiation therapy (RT) is the standard of care, although it offers
temporary relief of symptoms rather than a real hope of cure (4). Despite 68 clinical trials using
various adjuvant chemotherapeutic agents between 1984 and 2014, there has been no improvement
in survival compared to radiation alone, and DIPG are currently the number one cause of brain
tumor related death in children (5–18). Themedian survival of DIPG patients is only 10months post
diagnosis and <10% of patients survive 2 years (19, 20). Since the 1980s, the diagnosis of DIPG was
based on clinical findings and diagnostic imaging characteristics on computerized tomography (CT)
or magnetic resonance imaging (MRI) (4, 21). The lack of surgical and biopsy material has limited
most studies of DIPG biology and histology to post-mortem tissue. Although initial investigation
into the safety of incorporating biopsy for BSG showed no surgical mortality and low surgical
morbidity (22), the advent of CT and MRI allowed for accurate non-invasive localization of BSG
(23). It was noted that patients with DIPG represented the majority of deaths in children with BSG
and biopsies, which did not stratify patients into different treatment groups, were abandoned (23).
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Recently, the role for biopsy in DIPG diagnosis has been substan-
tially strengthened due to several important discoveries related to
the biology and histopathology of this universally fatal tumor (3,
24, 25) and successful use of stereotactic biopsy by several centers
with limited morbidity (26–29). Biologically, DIPG is a unique
tumor entity which possesses properties that are antithetical when
compared to other brain tumors, such as pediatric and adult
supratentorial high-grade astrocytomas (HGA), which they most
often resemble histologically. This review highlights the unique
pathology, genetics, and epigenetics of DIPG.
From Candidate Gene Approaches to
Next-Generation Sequencing
Early molecular profiling of pediatric gliomas was limited to
candidate gene approaches (30–33) focusing on mutational and
copy number profiling of genes known to be frequently impli-
cated in adult HGA, namely EGFR, TP53, IDH1/2, CDKN2A,
MGMT, and PTEN (34–36). All early studies of DIPG were
performed on small cohorts or case studies, which limited their
usefulness in defining the biology of this deadly pediatric can-
cer. However, conclusions from these studies still highlighted
some differences between DIPG and adult HGA. Unfortunately,
these candidate gene approaches were limited to what was known
about adultHGAand future studies usingwhole-genomeprofiling
approaches would be required to discover more robust differences
between these entities.Whole genome profiling technologies such
as array CGH and SNP-genotyping allowed for the first genome-
wide copy number analysis of cancers. Although giving a low reso-
lution perspective at first, newer iterations allowed for greater and
greater resolution and began to highlight the unique molecular
profiles of DIPG when compared to pediatric and adult supra-
tentorial astrocytomas. Copy number signatures at the whole
chromosome arm level revealed differences between DIPG and
adult HGA (37). Gains of chromosome 1q and losses of 11p, 13q,
and 14q were frequently observed in DIPG and less so in supra-
tentorial HGA (37). Subsequent copy number studies, with larger
DIPG patient tumor cohorts, revealed frequently altered genes
(Table 1) including PDGFRA, TP53, PARP1, PVT-1/MYC, RB1,
and PTEN (3, 38, 39). Most recently, next-generation sequencing
approaches, including whole-genome sequencing (WGS), whole-
exome sequencing (WES), and RNA-sequencing integrated with
histopathology, copy number, gene expression, and methylation
profiling, and other molecular techniques have re-defined what
we know about DIPG genetics and epigenetics.
Mutational Landscape
The first major breakthrough in defining the DIPG mutational
landscape came in 2012, when studies on pediatric brain tumors
using whole-genome and WES reported that 70–84% of DIPG
possess mutations in histone H3, and that these mutations were
predictive of outcome (3, 24, 25). These recurrent mutations, in
H3F3A or HIST1H3B/C/I (Figure 1A), result in a p. Lys27Met
(K27M) substitution. A subset of other midline astrocytomas,
such as those arising in the thalamus, have also been found to
harbor K27M histone H3 mutations although at a lower fre-
quency (50). Conversely, pediatric supratentorial HGA rarely
TABLE 1 | Frequencies of most common mutations and copy number
alterations in diffuse intrinsic pontine glioma from the literature.
Gene Alteration type Frequency
in DIPG (%)
Reference
ACVR1 Mutation 20–32 (40–42)
ATRX Mutation 9–13 (3, 24)
BRAF Mutation 0 (40–43)
CDK6 Copy number gain 3–4 (3, 37, 44)
CDKN2A/B Focal deletion 3–4 (37–39)
EGFR Mutation 0–2 (40–43, 45)
Amplification 0–2
FGFR Fusion 0 (40–43)
H3F3A Mutation 58–65 (3, 40–43, 46)
HIST1H3B/C Mutation 12–19 (40–43, 46)
IDH1/2 Mutation 0 (3, 40–43, 46)
MYC/PVT-1 Copy number gain 14 (3, 40)
MYCN Copy number gain 7 (3, 40)
NF1 Mutation 0–3 (40–43)
Focal deletion 7
PDGFRA Mutation 5–9 (3, 37, 38, 40, 47, 48)
Copy number gain 28–36
PIK3CA Mutation 12–23 (2, 27)
PPM1D Mutation 10–12 (42, 46)
TP53 Mutation 42–71 (2, 3, 32, 40, 49)
Heterozygous deletion 35–64
PTEN Mutation 0–3
Focal deletion 14 (38–43)
RB1 Mutation 0 (3, 38–43)
Focal deletion 16
possess these mutations, and more frequently have p. Gly34Arg
(G34R) or p. Gly34Val (G34V) substitution in histone H3.3.
The G34R/V-H3.3 mutations occur in 10–19% of supratentorial
HGA cases (24) and are never found in DIPG (3). Furthermore,
among supratentorial GBM, these G34R/V-H3.3 mutations are
predominantly found in older children and young adults (3).
Mutations affecting these two histone residues are extremely rare
in adult HGA.
Histones are proteins that form octomeric complexes known
as nucleosomes around which DNA wraps and condenses into
chromatin. The majority of histone mutations in DIPG, 65%,
effect histone variant H3.3 (3, 24, 25). Although this histone is
coded in two genes,H3F3A andH3F3B, K27Mmutations are only
found in the former. K27M-H3.1 mutations are found in 12–19%
of DIPG and are mutually exclusive from K27M-H3.3 mutations
(24, 40). Histone H3.1 is coded by a cluster of 10 genes on chro-
mosome 6 known as the HIST1 cluster (44). Currently, K27M-
H3.1 mutations have been detected in HIST1H3B, HIST1H3C,
and HISTIH3I.
Histones play a key role in the state of chromatin; however, they
themselves do not determine whether chromatin will be in a con-
formation more permissive to gene expression (euchromatin) or
in a conformation less permissive to gene expression (heterochro-
matin). Several histone marks can be laid on specific residues
across the histone tail, including lysine 27, which can be post-
translationally modified by either acetylation or mono-, di-, or
tri- methylation (51–53). Various cellular machineries are impli-
cated in the reading, writing, and copying of these epigenetic his-
tone marks, including histone acetyltransferases (HATs), histone
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FIGURE 1 | Schematic of residue alterations in (A) histone H3,
(B) TP53, (C) PPM1D, and (D) ACVR1 as a result of mutations most
frequently identified in DIPG. GD, globular domain; TD, transactivation
domain; OD, oligomerization domain; BD, basic domain; CID, CHEK1
interacting domain; GSD, GS domain; PKD, protein Kinase domain. Red
indicates most frequently altered amino acid.
deacetylases (HDACs), histone methyltransferases (HMTs), and
histone demethylases (54). The methionine substitution at K27 in
DIPG cannot be modified and several in vitro and in vivo studies
have documented a global decrease in H3K27me3 in the presence
ofmutant histone (40, 55–58). This global decrease is attributed to
polycomb repressive complex 2 (PRC2) inhibition (59); however,
othermolecular consequences of thismutation, including its effect
on histone marks, global DNA methylation, and gene expression,
are still under investigation. Histone H3 mutations are undoubt-
edly important in DIPG tumorigenesis and/ormaintenance but in
amajority of cases are found to be partnered with other mutations
and copy number alterations (CNAs) (3, 40), suggesting that they
are not the sole drivers of DIPG tumorigenesis.
TP53 mutations and CNAs occur in 42–71% of DIPG
(Figure 1B) (3, 40). Hemizygous deletions are often associated
with a mutation and strong protein expression by immunohisto-
chemistry (32, 49). Interestingly, DIPG with low-grade astrocy-
toma histology (grade II), even those harboring H3-mutations,
are not mutated for TP53 (2). Among DIPG with high-grade
histology (grade III and IV), bothH3-mutant andwild-typeDIPG
often have mutated TP53 (2). However, a recent exome sequenc-
ing study identified PPM1D mutations (Figure 1C) in a subset
of H3-mutant but TP53 wild-type DIPG (46). These mutations
account of ~50% of TP53 wild-type grade II DIPG. PPM1D gene
codes for WIP1 (wild-type p53-induced protein phosphatase 1D)
and has been implicated as an oncogene in other cancers (60–
62). Mutations of PPM1D have been shown to be functionally
equivalent to those of TP53 (46, 63). Taken together, alterations of
theTP53 signaling pathway inDIPG are only slightly less common
than histone H3 mutations.
The third most commonly mutated gene in DIPG codes for
the activin A receptor, type I (ACVR1), a member of the bone
morphogenic protein (BMP) signaling pathway. Approximately,
20–32% of DIPG harbor mutations in ACVR1 which significantly
overlap with K27Mmutations in histoneH3.1 (40–42). Previously
only reported in a congenital autosomal dominant disease of
the connective tissue called fibrodysplasia ossificans progressiva
(FOP), ACVR1 mutations result in ligand-independent constitu-
tive activation of the BMP signaling pathway (64–66). Although
seven differentACVR1mutations have been reported inDIPG, the
most common alteration in this tumor type, p.Gly328Val, has not
been reported in FOP patients. Several other residues of ACVR1
are frequently mutated in DIPG (Figure 1D). These mutations
have been shown to increase levels of phosphorylated SMAD1/5
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(40–43) as well as increased gene expression of downstream BMP
signaling targets ID1 and ID2 (40). Research into the cooperation
between ACVR1 and histone H3.1 mutations, and their effects on
tumorigenesis are still ongoing.
Amplification and Mutations of Receptor
Tyrosine Kinases
Receptor tyrosine kinases (RTKs) are cell surface receptors which
are often dysregulated in cancers. The RTK/RAS/PI-3K signaling
pathway is the most commonly dysregulated signaling pathway in
adult GBM, with 90% of tumors exhibiting CNAs or mutations
in pathway members (34). Mutations and CNAs in the platelet-
derived growth factor receptor alpha (PDGFRA) have been impli-
cated in both adult and pediatric HGA. Several array based studies
of DIPG revealed amplification of PDGFRA in 28–36% of patient
tumors (37, 38). The frequency of these amplifications in pedi-
atric and adult supratentorial HGA was reported in the range of
7–14%, and was preferentially identified in the Proneural subtype
of adult GBM (36). In DIPG, PDGFRA amplifications are exclu-
sively found in patients with K27M-H3 mutations and across all
astrocytic histologies (grade II-IV) (2, 40). Oncogenic mutations
of PDGFRA have also been reported in 5–9% of DIPG (47, 48).
Epidermal growth factor receptor (EGFR) copy number gains
and mutations are among the most frequent alterations in adult
HGA, occurring in 60–85% of GBM (34, 35). In adults, EGFR
protein expression correlates with amplifications and EGFRvIII
mutations; however in DIPG, EGFR CNAs and mutations are
extremely rare, found in 0–2% of patient tumors (45), and do not
correlate with immunopositivity (67, 68). The RTK/RAS/PI-3K
signaling pathway is further dysregulated in DIPG through hem-
izygous deletions of PTEN (40), as well as mutations of PIK3CA
andPIK3R1 (2, 27). Although this pathway has often been targeted
in clinical trials, the majority of the CNAs and mutations in the
RTK/RAS/PI-3K pathway are clonal events, as determined by flu-
orescence in situhybridization (FISH) forPDGFRA amplifications
(37) and mutation allele frequency of PIK3CA, suggesting these
events likely arise later in tumor development.
DNA Damage Repair (PARP1, MGMT, MPG)
Radiotherapy is the standard of care for DIPG and adjuvant
chemotherapeutics have been shown to be ineffective. Pertur-
bations in DNA damage repair pathways in DIPG were first
identified in 2010 by Zarghooni et al. Loss of heterozygosity
(LOH) was identified in many genes involved in nucleotide exci-
sion repair, non-homologous end-joining (NHEJ), homologous
recombination (HR), base excision repair (BER), and mismatch
repair (MMR) by analysis of both SNP arrays and microsatellite
markers (37). Poly (ADP-ribose) polymerase (PARP1), a protein
essential for repair of single strand DNA breaks induced by alky-
lating agents, as well as repair of ionizing radiation induced double
strand breaks by HR and NHEJ were found to be gained and/or
overexpressed in 54% of DIPG, highlighting it as a potential
therapeutic target (37). Furthermore, pathway analysis revealed
a subset of patients with LOH or deletions in members of the
BRCA DNA damage response pathway, including BRCA1 and
BRCA2. Defects in either of these two genes have been implicated
in promoting sensitivity to single strand DNA repair via PARP
inhibition.
Temozolomide (TMZ) is a frontline DNA alkylating agentmost
often used in treatment of adult GBM. TMZ causes DNA damage
by alkylating O6-guanine, N7-guanine, and N3-adenine residues.
In adults, it was identified that a subgroup of patients withMGMT
(O6-methylguanine DNA methyltransferase) promoter methyla-
tion had improved overall survival when treatedwith radiotherapy
and concomitant TMZ compared to patients without MGMT
promoter methylation (69). MGMT repairs TMZ alkylated O6-
guanine nucleotides. However, the universal lack of response to
TMZ in DIPG patients could not be attributed to this resistance
mechanism, as DIPG have not been found to express MGMT
(37). It has been recently described that TMZ resistance in the
pediatric population can be attributed to an ATM-dependent reg-
ulation of 3-methylpurine-DNA glycosylase (MPG), an enzyme
responsible for repair of alkylated N7 guanine and N3 adenine
residues (70). Further investigation into using radio-sensitizing
and chemo-sensitizing agents in DIPG therapy is warranted.
Isocitrate Dehydrogenase, ATRX, and
Telomeres
Mutations in the mitochondrial enzyme gene, isocitrate dehy-
drogenase 1 (IDH1), whose gene product catalyzes the oxidative
decarboxylation of isocitrate to α-keto glutarate, are found in
approximately 70–80% of adult low-grade astrocytomas (LGA)
and anaplastic astrocytomas (AA), as well as secondary glioblas-
toma (GBM) (71). Furthermore, in adult gliomas, IDH1mutations
were found to be associated with ATRX mutations and alternative
lengthening of telomeres (ALT) (72). Isocitrate dehydrogenase 2
(IDH2) mutations are also found in a subset of adult HGA but to
date, no mutations in IDH1 or IDH2 have been detected in DIPG.
Mutations of chromatin remodeling genes are less common in
DIPG than in supratentorial HGA (3, 24). ATRX, which codes for
the α-thalassemia/mental retardation syndrome X-linked gene,
was found to bemutated in a subset of DIPG (~9%) but in contrast
to pediatric supratentorial HGA, had no clear overlapwith histone
H3 mutations (3). Pediatric supratentorial HGA showed high
overlap with ATRX or DAXX mutations (15–25%) and G34R/V-
H3.3 alterations, as well asmutual exclusivity of IDH1/2mutations
(24, 73). Irrespective of tumor location, in the pediatric population
ATRX mutations significantly overlap with TP53 mutations and
are predominantly found in older children (3). ATRX and DAXX
(death-domain associated protein) are genes encoding subunits of
a chromatin remodeling complex required for histone H3.3 incor-
poration at telomeric regions. Telomeres are repetitive regions of
DNA found on the ends of chromosomes and shorten during
every cell division due to incomplete DNA replication (74). Over
many cell divisions, telomeres may reach a critically short length,
which results in cellular senescence (75). This fate can be avoided
by expressing telomerase, an enzyme that can extend telomeres.
Although telomerase is not expressed in most mature, terminally
differentiated cells (76, 77), its expression and activity has been
implicated in several brain cancers as a poor prognostic marker
and potential therapeutic target (78–80). Extension of telomeres
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in certain cancers can be attained by a telomerase independent
mechanism known as alternative lengthening of telomeres (ALT).
Twenty percent of DIPG test positive for ALT by either TRF
(telomere restriction fragment) assay or C-circles assay and ALT
positive DIPG are exclusive carriers of the K27M-H3.3 mutation
(40). ALT phenotype is also associated with an older age of diag-
nosis in DIPG and to date has not been detected in patients with
low-grade astrocytoma histology (2, 40).
DIPG Histopathology
Diffuse intrinsic pontine glioma is a heterogeneous disease, and
represents a varied histological spectrum. These tumors are very
diffuse and often involve adjacent brain structures beyond the
pons. Several studies report leptomeningeal dissemination and
subventricular spread as a common occurrence seen in as many
as one-third of DIPG, with tumor cells found as far rostrally as
the frontal lobe (2, 81, 82). A review by Jansen et al. reported
WorldHealthOrganization (WHO) central nervous system tumor
classification on 108 biopsies from 13 studies, including 37 AA
(WHO grade III), 27 GBM(WHO grade IV), 22 LGA (WHO
grade II), 3 anaplastic oligoastrocytomas (WHOgrade III), and 19
tumors with “not further specified” or undefined characterization
(9). Data from this biopsy series would suggest that WHO grade
III AA are the most common histological entity in brainstem
glioma; however, autopsy based histopathological studies report
WHO grade IV GBM to be the most common histology, poten-
tially highlighting the caveat of limited tissue sampling during
biopsy or anaplastic progress and/or treatment effect seen in late
stage disease at autopsy. Autopsy based studies revealed that GBM
histology wasmost common in DIPG. Of the 33 pediatric patients
examined by Yoshimura et al., 29 were reported to be GBM and
4 with anaplastic astrocytoma histology (83). A larger autopsy
based study of DIPG histology reported 42 GBM, 18 anaplastic
astrocytoma, 8 low-grade astrocytoma, and 2 with features of
primitive neuroectodermal tumor (PNET, WHO grade IV) (13).
FIGURE 2 | H&E staining of tissue sections from an autopsy of a
K27M-H3.1 mutant diffuse intrinsic pontine glioma patient highlights
vast regional differences that histologically resemble (A,B) high grade
astrocytoma (WHO grade III–IV) or (C) low grade astrocytoma (WHO
grade II). Inadvertently targeting these regions on biopsy could lead to
misdiagnosis. Histone H3 mutation predicts overall survival better than
histologic grade for DIPG. Mutational testing at the time of stereotactic biopsy
should be implemented into clinical practice for DIPG patients.
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Previous investigations into DIPG histology have also observed
this rare PNET histology in the brainstem (84). Importantly,
regional differences within one DIPG specimen can bias biopsy
based diagnoses. Autopsy studies allow extensive tissue sampling
and have highlighted intratumoral histopathologic heterogeneity
(2). Areas within or around a grade IV astrocytoma may present
with features of grade II or grade III histology that could be
inadvertently targeted at biopsy (Figure 2).
Perhaps most importantly, DIPG histology is not a predictor
of survival. Patients with low-grade histology do just as poorly as
patients with high-grade histology. On multivariate Cox regres-
sion analysis, only histone H3 mutation is a predictor of worse
FIGURE 3 | Summary of five publications between 2011 and 2014
outlining clinical and molecular features of diffuse intrinsic pontine
gliomas based on various platforms and sample sizes; Paugh et al. (38),
three subgroups – n=27; Puget et al. (48), two subgroups – n=23;
Khuong-Quang et al. (3), two subgroups – n=42; Saratsis et al. (85), two
subgroups – n=14; Buczkowicz et al. (40), three subgroups – n=48.
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overall survival, irrespective of histological grade, age of diagnosis,
and sex (2, 3). Furthermore, DIPG patients, which at autopsy had
grade II histology, but were mutated for histone H3, had clinical
outcomes similar to what would be expected of high-grade tumors
(2, 3). This important finding suggests brainstem glioma require
their own WHO grading scheme, which needs to incorporate
H3-mutation testing at biopsy.
Molecular Subgroups of DIPG
Several studies have embarked onmolecular subgrouping ofDIPG
based on various molecular signatures, including gene expression
profiling, copy number analysis, proteomics, mutational profiles,
and methylation profiling (Figure 3). A study by Paugh et al.
in 2011 profiled 27 DIPG by gene expression arrays and classi-
fied them into three subgroups based on hierarchical clustering
and compared the subgroup specific enrichment scores to previ-
ously identified subgroups of adult GBM, highlighting significant
enrichment in either mesenchymal, proliferative, or pronerual
markers (38). These data were also compared to genomic copy
number abnormalities determined by single-nucleotide polymor-
phism arrays which highlighted frequent focal amplifications of
PDGFRA and RB1. However, these CNAs were not restricted to
any of the three identified subgroups. A subsequent study of gene
expression profiles from 23 DIPG matched with copy number
data from array CGH identified two subgroups using K-means
clustering (48). These two subgroups were enriched for mes-
enchymal and proneural markers, respectively, with the proneural
subgroup displaying oligodendroglial features and alterations of
PDGFRA (48). With the discovery of histone mutations in ~80%
of DIPG in 2012 and their clinical relevance in patient survival,
supervised analysis of CNAs in wild-type and histone mutant
subgroups by single-nucleotide polymorphism arrays highlighted
PDGFRA and PVT-1/MYC gains and amplifications to be present
at high frequency in K27M-H3 mutant DIPG, whereas wild-
type DIPG were enriched forMYCN amplification as determined
by GISTIC2.0 analysis (3). A study from 2013 by Saratsis et al.
utilized mRNA and methylation profiles with protein profil-
ing of 14 DIPG specimens. This study also reported two sub-
groups, which were characterized by upregulation of N-Myc
or Hedgehog signaling through mRNA expression and DNA
hypomethylation (85).
Themost comprehensive subgrouping of DIPG integrated CpG
islandmethylationwithWGSandWES, gene expression, and copy
number profiling to find that DIPG are three molecularly dis-
tinct subgroups; MYCN, Silent, and H3-K27M (40). The MYCN
subgroup did not contain any DIPG with histone mutations,
but was characterized by high-level amplifications of MYCN and
ID2 genes caused by chromothripsis on chromosome 2p. Fur-
thermore, these MYCN amplified DIPG did not contain PVT-
1/MYC, PDGFRA, orRB1CNAs, whichwere previously described
to be common in these brainstem neoplasms (40). The Silent
subgroup did not contain many CNAs or mutations. In fact, this
subgroup was characterized by stable genomes when compared to
both MYCN and H3-K27M subgroup DIPG. Some DIPG in this
subgroup contained histone H3, TP53, and ACVR1 mutations;
however, they were found at a lower frequency. All patients within
the largest subgroup, H3-K27M, had histone H3-mutations. This
subgroup was further characterized by hypomethylated genomes
and also enriched in ACVR1 mutations (which significantly
co-occurred with K27M-H3.1 mutations), TP53/PPM1D muta-
tions/homozygous deletions, alternative lengthening of telomeres,
and CNAs of PVT-1/MYC, PTEN, PDGFRA, and RB1 (40).
Conclusion
In recent years, the combined increase in knowledge of DIPG
histology, genetics, and epigenetics has been substantial. Muta-
tions in previously undiscovered oncogenes, histone H3, and
ACVR1, molecular subtypes of DIPG, and the rediscovered role
for biopsy for this tumor entity are redefining what is clinically
possible in treating these patients. The major challenges ahead are
developing molecularly accurate pre-clinical models for testing
of new therapeutics and integrating new genetic/epigenetic and
histopathological knowledge for DIPG patient diagnosis, treat-
ment, and future clinical trial design. In the near future, DIPG
patients will benefit from mutational testing and molecular sub-
grouping at biopsy, which will provide more accurate prognosis
and actionable tumor-specific genomic targets for these affected
children.
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